A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Completed
Incyte Corporation
Phase 1/Phase 2
Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to
find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor,
parsaclisib, as monotherapy and in combination with: itacitinib (INCB039110), a JAK1
inhibitor; rituximab; and rituximab, ifosfamide, carboplatin, and etoposide. Parsaclisib
inhibits PI3Kδ, a protein involved in growth and survival of B-cell cancer cells.
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Active, not recruiting
Incyte Corporation
Phase 2
The purpose of this study is to evaluate the safety, tolerability, and efficacy of the
combination of parsaclisib and ruxolitinib in subjects with myelofibrosis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
